Clinical Scorecard: Long-term Assessment of Motor Function and Biomarker Associations in Adults with Treated Spinal Muscular Atrophy: Findings from a Single-Center Study
At a Glance
Category
Detail
Condition
Spinal Muscular Atrophy (SMA)
Key Mechanisms
Genetic mutations in SMN1 and SMN2 affecting motor neuron function.
Target Population
Adults with genetically confirmed 5q-SMA treated with nusinersen or risdiplam.
Care Setting
Single-center longitudinal observational study.
Key Highlights
Longitudinal study of 23 adults with SMA over a mean follow-up of 57 months.
Higher SMN2 copy number linked to later onset and milder severity.
Motor scores improved or stabilized in the first year post-treatment, followed by plateau or decline in some patients.
Vital capacity (%VC) and biomarkers like CK and ulnar CMAP amplitude associated with motor status.
Prediction of treatment responsiveness remains challenging.
Guideline-Based Recommendations
Diagnosis
Genetic confirmation of 5q-SMA through SMN1 and SMN2 analysis.
Management
Treatment with nusinersen (12 mg intrathecal) or risdiplam (5 mg/day orally).
Monitoring & Follow-up
Regular assessments using RULM, HFMSE, and biomarkers like %VC and CK.
Risks
Potential for variability in treatment response and motor function outcomes.
Patient & Prescribing Data
Adults with genetically confirmed 5q-SMA.
Nusinersen and risdiplam have transformed the natural history of SMA, but long-term outcomes are still being characterized.
Clinical Best Practices
Utilize simple clinical measures for routine monitoring of motor function.
Consider SMN2 copy number as a key determinant of disease severity.
